Skip to content
The Inflation Reduction Act (IRA) has been top of mind for many in the biotech industry. The first round of price negotiations and the […]
BIF 2024: ‘The IRA really disrupted how we think’ Read More »
There is a great degree of renewed optimism for drug development in the neurodegenerative disease space. “Some of that optimism has obviously come from
BIF 2024: What’s happening with neurodegenerative disease targets and pipelines? Read More »
September was a big month for those following antimicrobial resistance (AMR). A new study highlighted the growing public health burden of AMR, and the
AMR continues to pose a global threat Read More »
Mpox has proven to be a major public threat since its resurgence globally during the COVID years. As Bio.News reported, “On Aug. 14, the
BIO speaks on Capitol Hill about mpox preparedness Read More »
September is Sepsis Awareness Month, and the Biotechnology Innovation Organization (BIO) is partnering with Sepsis Alliance to spread the word about sepsis and provide
Sepsis Awareness Month: 3 things you need to know about sepsis Read More »
Since 2019, the Biotechnology Innovation Organization (BIO) has worked with BBC StoryWorks Commercial Productions, the BBC’s award-winning branded content division, to bring stories of
BIO and BBC StoryWorks call for biotech stories Read More »
“The world of biotechnology is in the midst of a wave of exciting research and clinical advances—from artificial intelligence-based drug discovery to cell and
GEN State of Biotechnology 2024: John F. Crowley on driving biotech forward Read More »
Antimicrobial resistance (AMR) is one of the clear and present threats of our time, and if left unchecked could have dire consequences. In 2019,
BIO at the World AMR Congress: ‘We know we’re racing against time’ Read More »
The first shipment of Jynneos mpox vaccines arrived in the Democratic Republic of Congo (DRC) on Sept. 5, according to vaccine maker Bavarian Nordic.
First mpox vaccines arrive in DRC, epicenter of the international emergency Read More »
Afreen Allam’s company, SiNON Nano Sciences, has been working tirelessly to overcome one of the most significant challenges in neurology: enabling drugs to cross
BIO Start-Up Stadium 2024: Meet Seed-Stage winner Afreen Allam and SiNON Nano Sciences Read More »
